RxDoctor Payments DataLook up a doctor →

Steven Vanderbilt, APRN

Family · Jonesboro, ARNPI 1063977965

Payments from drug & device makers

$10,440in general payments, 2019–2025

Across 709 payments — averaging $14.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$881
  • Novo Nordisk$771
  • Amgen$480
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,440100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,440 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$79,317
Medicare patients
400
Services billed
3,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide65$70,588
OzempicSemaglutide54$58,288
JardianceEmpagliflozin58$53,636
LinzessLinaclotide36$23,316
MyrbetriqMirabegron43$21,583
EliquisApixaban24$21,292
RybelsusSemaglutide18$20,588
FarxigaDapagliflozin Propanediol15$14,934
EntrestoSacubitril/Valsartan16$12,600
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,552
KerendiaFinerenone12$8,065
BelsomraSuvorexant18$7,662
Dexlansoprazole DrDexlansoprazole15$6,231
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,292
JanumetSitagliptin Phos/Metformin Hcl11$3,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$771$78,87672 claims
Lilly USA, LLCMounjaro$881$70,58865 claims
Boehringer IngelheimJardiance, Stiolto Respimat$199$58,92869 claims
PfizerEliquis, Premarin$1,208$23,67035 claims
AbbVieLinzess$1,295$23,31636 claims
Astellas Pharma US IncMyrbetriq$297$21,58343 claims
AstraZenecaFarxiga$1,034$14,93415 claims
NovartisEntresto$331$12,60016 claims
GSKTrelegy Ellipta$452$11,55218 claims
MerckBelsomra, Janumet$233$11,52729 claims
BayerKerendia$446$8,06512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →